Abstract: At least one device can be classified based on user activity. At least one telemetry variable with respect to time may be received for the at least one device. The at least one telemetry variable with respect to time may be used to determine an activity model for the at least one device. Based on the activity model, a probability of the at least one device belonging to a profile or to a type of user may be determined. Based on the type of user of the at least one device, a setting associated with the at least one device may be changed.

Abstract: The present application relates to novel substituted imidazo[4,5-c]cinnolin-2-one compounds and pharmaceutically acceptable salts thereof, which selectively modulate ataxia telangiectasia mutated (“ATM”) kinase. The present application also relates to pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and to the use of the compounds and salts thereof in the treatment of ATM-associated diseases or conditions, including cancers.

Abstract: It is disclosed crystalline forms of (R)-N-(4-([1, 2, 4]triazolo [1, 5-c]pyrimidin-7-yloxy)-3-methylphenyl)-5-((3, 3-difluoro-1-methylpiperidin-4-yl)oxy)-6-methoxyquinazolin-4-amine, methods for the preparation thereof, pharmaceutical compositions comprising one or more of the crystalline forms as an active ingredient, and use of the crystalline forms in the treatment of hyperproliferative diseases.

Abstract: Provided novel compounds useful as KRAS G12D inhibitors, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.

Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Abstract: A combined display method includes: the mobile device broadcasts a first message in response to receiving a first input, where the first message indicates that the combined display needs to be performed; the mobile device obtains a first image, where the first image includes a first display and a second display, the first display displays first information, and the second display displays second information; the mobile device sends a second message to a first electronic device, where the second message includes the first information, the second information, orientation information of the first display and the second display, a size proportion relationship between the first display and the second display, and a correspondence between the first information and the first display; and the first electronic device controls, in response to receiving the second message, a plurality of electronic devices to perform combined display.

Abstract: The specification relates to imidazo [4,5-c] cinnolin-2-one compounds and pharmaceutically acceptable salts thereof, which selectively modulate ataxia telangiectasia mutated (“ATM”) kinase. The specification also relates to pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and to the use of the compounds and salts thereof in the treatment of ATM-associated diseases or conditions, including cancers.

Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Abstract: A power line communication-based pairing method and device for an air conditioner, and a storage medium are provided. Based on a pairing request instruction, A CCO module on an indoor side selects an STA module to be paired, in a power line network, for use as a pairing object. The CCO module sends pairing request information to the power line network. The STA module receives the pairing request information. If the STA module determines that identification information thereof exists in the pairing request information, the STA module establishes a pairing relationship with the CCO module. The STA module sends pairing feedback information to the power line network. The CCO module receives the pairing feedback information. If the CCO module determines that the identification information thereof exists in the pairing feedback information, the CCO module determines that the pairing is successful and establishes a pairing relationship with the STA module.

Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Abstract: A laser transmit module includes a capacitor, a laser transmitter, and a field effect transistor. The capacitor is configured to supply power to the laser transmitter. The field effect transistor is configured to control the laser transmitter to be turned on. The capacitor, the laser transmitter, and the field effect transistor are interconnected through conductive pins to form a laser transmission loop. Loop inductance generated by the laser transmission loop affects a pulse peak value of a laser pulse transmitted by the laser transmitter, thereby affecting a detection distance of the laser pulse. Therefore, the laser transmission loop is formed through a direct connection between the conductive pins of the capacitor, the laser transmitter, and the field effect transistor, to reduce distances between the components and reduce an area of the formed laser transmission loop, so as to increase the detection distance of the laser transmit module.

Abstract: The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

Abstract: The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

Abstract: Disclosed are compounds having the formula (I) wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.

Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Abstract: In some examples, a service provider may manage inventories of items by offering money advances to make inventory orders on behalf of a merchant. The service provider may determine a risk associated with advancing money to the merchant based on sales of items made by the merchant. The service provider may provide a money advance to the merchant when the risk associated with advancing money is within a threshold level. The money advance may be used to order inventory from a supplier. This may assist the merchant in managing inventory.

Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Abstract: At least one device can be classified based on user activity. At least one telemetry variable with respect to time may be received for the at least one device. The at least one telemetry variable with respect to time may be used to determine an activity model for the at least one device. Based on the activity model, a probability of the at least one device belonging to a profile or to a type of user may be determined. Based on the type of user of the at least one device, a setting associated with the at least one device may be changed.